Tumor-induced perturbations of cytokines and immune cell networks

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1845, Issue 2, 2014, Pages 182-201

  Burkholder, Brett ^a   Huang, Ren Yu ^a   Burgess, Rob ^a   Luo, Shuhong ^a   Jones, Valerie Sloane ^a   Zhang, Wenji ^a   Lv, Zhi Qiang ^a   Gao, Chang Yu ^a   Wang, Bao Ling ^a   Zhang, Yu Ming ^a   Huang, Ruo Pan ^a,b  

^a RayBiotech   (China)

^b South China Biochip Research Center   (China)

Author keywords

Cancer; Cytokine; Immunosuppression; Immunosurveillance

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PD 1 ANTIBODY; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIANGIOGENIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL GROWTH; CELL INTERACTION; CELL POPULATION; CYTOKINE RESPONSE; DENDRITIC CELL; DRUG SAFETY; DRUG TARGETING; HELPER CELL; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MAST CELL; MELANOMA; METASTASIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; STROMA CELL; SURVIVAL TIME; TH1 CELL; TH17 CELL; TH2 CELL; THYROID CANCER; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

CANCER; CYTOKINE; IMMUNOSUPPRESSION; IMMUNOSURVEILLANCE;

CELL COMMUNICATION; CYTOKINES; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSION; MONITORING, IMMUNOLOGIC; NEOPLASMS; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84896724633     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.01.004     Document Type: Review

References (163)

1. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309.
2. Paltridge J.L., Belle L., Khew-Goodall Y. The secretome in cancer progression. Biochim. Biophys. Acta 2013, 1834:2233.
3. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991.
4. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646.
5. Kim R., Emi M., Tanabe K., Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006, 66:5527.
6. DeNardo D.G., Coussens L.M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007, 9:212.
7. Marsh T., Pietras K., McAllister S.S. Fibroblasts as architects of cancer pathogenesis. Biochim. Biophys. Acta 2013, 1832:1070.
8. Huang R.P., Burkholder B., Jones V.S., Jiang W.D., Mao Y.Q., Chen Q.L., Shi Z. Cytokine antibody arrays in biomarker discovery and validation. Curr. Proteomics 2012, 9:55.
9. Celis J.E., Gromov P., Cabezon T., Moreira J.M., Ambartsumian N., Sandelin K., Rank F., Gromova I. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics 2004, 3:327.
10. Celis J.E., Moreira J.M., Gromova I., Cabezon T., Ralfkiaer U., Guldberg P., Straten P.T., Mouridsen H., Friis E., Holm D., Rank F., Gromov P. Towards discovery-driven translational research in breast cancer. FEBS J. 2005, 272:2.
11. Huang R.P. An array of possibilities in cancer research using cytokine antibody arrays. Expert. Rev. Proteomics. 2007, 4:299.
12. Korf U., Henjes F., Schmidt C., Tresch A., Mannsperger H., Lobke C., Beissbarth T., Poustka A. Antibody microarrays as an experimental platform for the analysis of signal transduction networks. Adv. Biochem. Eng. Biotechnol. 2008, 110:153.
13. Sanchez-Carbayo M. Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens. Tumour Biol. 2010, 31:103.
14. Chandra H., Reddy P.J., Srivastava S. Protein microarrays and novel detection platforms. Expert Rev. Proteomics 2011, 8:61.
15. Hudler P., Gorsic M., Komel R. Proteomic strategies and challenges in tumor metastasis research. Clin. Exp. Metastasis 2010, 27:441.
16. Jiang W.D., Huang R.P. Overcoming the deficiency of singular detection by antibody arrays in cancer biomarker discovery. J. Pathol. 2012, 3(12A.D.):132.
17. Kingsmore S.F. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat. Rev. Drug Discov. 2006, 5:310.
18. Ehrlich P. Ueber den jetzigen stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 1909, 5:273.
19. Wiemann B., Starnes C.O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 1994, 64:529.
20. Agrawal N., Bettegowda C., Cheong I., Geschwind J.F., Drake C.G., Hipkiss E.L., Tatsumi M., Dang L.H., Diaz L.A., Pomper M., Abusedera M., Wahl R.L., Kinzler K.W., Zhou S., Huso D.L., Vogelstein B. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15172.
21. Biragyn A., Longo D.L. Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses. Semin. Cancer Biol. 2012, 22:50.
22. de Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006, 6:24.
23. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436.
24. Verbeke H., Struyf S., Laureys G., Van D.J. The expression and role of CXC chemokines in colorectal cancer. Cytokine Growth Factor Rev. 2011, 22:345.
25. DeNardo D.G., Andreu P., Coussens L.M. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 2010, 29:309.
26. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883.
27. Haabeth O.A., Bogen B., Corthay A. A model for cancer-suppressive inflammation. Oncoimmunology 2012, 1:1146.
28. Braumuller H., Wieder T., Brenner E., Assmann S., Hahn M., Alkhaled M., Schilbach K., Essmann F., Kneilling M., Griessinger C., Ranta F., Ullrich S., Mocikat R., Braungart K., Mehra T., Fehrenbacher B., Berdel J., Niessner H., Meier F., van den B.M., Haring H.U., Handgretinger R., Quintanilla-Martinez L., Fend F., Pesic M., Bauer J., Zender L., Schaller M., Schulze-Osthoff K., Rocken M. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013, 494:361.
29. Pages F., Galon J., Dieu-Nosjean M.C., Tartour E., Sautes-Fridman C., Fridman W.H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29:1093.
30. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298.
31. Ma J., Liu L., Che G., Yu N., Dai F., You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010, 10:112.
32. Senovilla L., Vacchelli E., Galon J., Adjemian S., Eggermont A., Fridman W.H., Sautes-Fridman C., Ma Y., Tartour E., Zitvogel L., Kroemer G., Galluzzi L. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012, 1:1323.
33. Aggarwal B.B., Vijayalekshmi R.V., Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 2009, 15:425.
34. Brenner H., Rothenbacher D., Arndt V. Epidemiology of stomach cancer. Methods Mol. Biol. 2009, 472:467.
35. Peinado H., Lavotshkin S., Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 2011, 21:139.
36. Kostadinov R.L., Kuhner M.K., Li X., Sanchez C.A., Galipeau P.C., Paulson T.G., Sather C.L., Srivastava A., Odze R.D., Blount P.L., Vaughan T.L., Reid B.J., Maley C.C. NSAIDs modulate clonal evolution in Barrett's esophagus. PLoS Genet. 2013, 9:e1003553.
37. Whiteside T.L., Herberman R.B. The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol. 1995, 7:704.
38. Gabrilovich D.I., Corak J., Ciernik I.F., Kavanaugh D., Carbone D.P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 1997, 3:483.
39. Bosma M.J., Carroll A.M. The SCID mouse mutant: definition, characterization, and potential uses. Annu. Rev. Immunol. 1991, 9:323.
40. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7556.
41. Trapani J.A., Smyth M.J. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2002, 2:735.
42. van den Broek M.E., Kagi D., Ossendorp F., Toes R., Vamvakas S., Lutz W.K., Melief C.J., Zinkernagel R.M., Hengartner H. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 1996, 184:1781.
43. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245.
44. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006, 6:836.
45. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011, 29:235.
46. Mocellin S., Nitti D. CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochim. Biophys. Acta 2013, 1836:187.
47. Intlekofer A.M., Thompson C.B. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 2013, 94:25.
48. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565.
49. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7:41.
50. Slaney C.Y., Rautela J., Parker B.S. The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res. 2013, 73:5852.
51. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482:405.
52. Dunn G.P., Sheehan K.C., Old L.J., Schreiber R.D. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 2005, 65:3447.
53. Okada H., Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 2004, 4:592.
54. Ito K., Stannard K., Gabutero E., Clark A.M., Neo S.Y., Onturk S., Blanchard H., Ralph S.J. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev. 2012, 31:763.
55. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734.
56. Sato Y., Goto Y., Narita N., Hoon D.S. Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2009, 2(Suppl. 1):205.
57. Torroella-Kouri M., Silvera R., Rodriguez D., Caso R., Shatry A., Opiela S., Ilkovitch D., Schwendener R.A., Iragavarapu-Charyulu V., Cardentey Y., Strbo N., Lopez D.M. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res. 2009, 69:4800.
58. Amsen D., Spilianakis C.G., Flavell R.A. How are T(H)1 and T(H)2 effector cells made?. Curr. Opin. Immunol. 2009, 21:153.
59. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71.
60. Sica A., Schioppa T., Mantovani A., Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 2006, 42:717.
61. Roca H., Varsos Z.S., Sud S., Craig M.J., Ying C., Pienta K.J. CCL2 and interleukin-6 promote survival of human CD11b+peripheral blood mononuclear cells and induce M2-type macrophage polarization. J. Biol. Chem. 2009, 284:34342.
62. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 2008, 99:1501.
63. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39.
64. Miyagawa S., Soeda J., Takagi S., Miwa S., Ichikawa E., Noike T. Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum. Pathol. 2004, 35:1392.
65. Cai X.Y., Gao Q., Qiu S.J., Ye S.L., Wu Z.Q., Fan J., Tang Z.Y. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2006, 132:293.
66. Coventry B.J., Morton J. CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer. Br. J. Cancer 2003, 89:533.
67. Kohrt H.E., Nouri N., Nowels K., Johnson D., Holmes S., Lee P.P. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2005, 2:e284.
68. Sharma S., Stolina M., Yang S.C., Baratelli F., Lin J.F., Atianzar K., Luo J., Zhu L., Lin Y., Huang M., Dohadwala M., Batra R.K., Dubinett S.M. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin. Cancer Res. 2003, 9:961.
69. Stolina M., Sharma S., Lin Y., Dohadwala M., Gardner B., Luo J., Zhu L., Kronenberg M., Miller P.W., Portanova J., Lee J.C., Dubinett S.M. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 2000, 164:361.
70. Wu C.Y., Wang K., McDyer J.F., Seder R.A. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J. Immunol. 1998, 161:2723.
71. Yang A.S., Lattime E.C. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res. 2003, 63:2150.
72. Obermajer N., Muthuswamy R., Lesnock J., Edwards R.P., Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011, 118:5498.
73. Angelo L.S., Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin. Cancer Res. 2007, 13:2825.
74. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., Kroemer G., Martin F., Chauffert B., Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 2005, 202:919.
75. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182:4499.
76. Gabitass R.F., Annels N.E., Stocken D.D., Pandha H.A., Middleton G.W. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 2011, 60:1419.
77. Mattei F., Schiavoni G., Sestili P., Spadaro F., Fragale A., Sistigu A., Lucarini V., Spada M., Sanchez M., Scala S., Battistini A., Belardelli F., Gabriele L. IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. Neoplasia 2012, 14:1223.
78. Ostrand-Rosenberg S., Sinha P., Beury D.W., Clements V.K. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin. Cancer Biol. 2012, 22:275.
79. Watkins S.K., Egilmez N.K., Suttles J., Stout R.D. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J. Immunol. 2007, 178:1357.
80. Talmadge J.E. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 2007, 13:5243.
81. Yan H.H., Pickup M., Pang Y., Gorska A.E., Li Z., Chytil A., Geng Y., Gray J.W., Moses H.L., Yang L. Gr-1+CD11b+myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res. 2010, 70:6139.
82. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22:531.
83. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942.
84. Pan P.Y., Ma G., Weber K.J., Ozao-Choy J., Wang G., Yin B., Divino C.M., Chen S.H. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2010, 70:99.
85. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123.
86. Ruffell B., DeNardo D.G., Affara N.I., Coussens L.M. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010, 21:3.
87. Akhurst R.J., Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol. 2001, 11:S44-S51.
88. Yang L., Pang Y., Moses H.L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010, 31:220.
89. Nam J.S., Terabe M., Kang M.J., Chae H., Voong N., Yang Y.A., Laurence A., Michalowska A., Mamura M., Lonning S., Berzofsky J.A., Wakefield L.M. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 2008, 68:3915.
90. Kim B.G., Li C., Qiao W., Mamura M., Kasprzak B., Anver M., Wolfraim L., Hong S., Mushinski E., Potter M., Kim S.J., Fu X.Y., Deng C., Letterio J.J. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 2006, 441:1015.
91. Meulmeester E., Ten D.P. The dynamic roles of TGF-beta in cancer. J. Pathol. 2011, 223:205.
92. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298.
93. Izhak L., Wildbaum G., Jung S., Stein A., Shaked Y., Karin N. Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis. PLoS One 2012, 7:e28305.
94. Ma J., Wang Q., Fei T., Han J.D., Chen Y.G. MCP-1 mediates TGF-beta-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 2007, 109:987.
95. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., Carbone D.P., Matrisian L.M., Richmond A., Lin P.C., Moses H.L. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+myeloid cells that promote metastasis. Cancer Cell 2008, 13:23.
96. Bierie B., Stover D.G., Abel T.W., Chytil A., Gorska A.E., Aakre M., Forrester E., Yang L., Wagner K.U., Moses H.L. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res. 2008, 68:1809.
97. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263.
98. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2:1096.
99. Hao Q., Wang L., Tang H. Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells. Am. J. Physiol. Cell Physiol. 2009, 296:C821-C827.
100. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749.
101. Sakamoto K., Maeda S., Hikiba Y., Nakagawa H., Hayakawa Y., Shibata W., Yanai A., Ogura K., Omata M. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin. Cancer Res. 2009, 15:2248.
102. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009, 4:e7965.
103. Theoharides T.C., Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol. 2004, 25:235.
104. Chomarat P., Banchereau J., Davoust J., Palucka A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 2000, 1:510.
105. Dumitru C.A., Lang S., Brandau S. Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin. Cancer Biol. 2013, 23:141.
106. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., Worthen G.S., Albelda S.M. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009, 16:183.
107. Tecchio C., Scapini P., Pizzolo G., Cassatella M.A. On the cytokines produced by human neutrophils in tumors. Semin. Cancer Biol. 2013, 23:159.
108. Houghton A.M. The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle 2010, 9:1732.
109. Jamieson T., Clarke M., Steele C.W., Samuel M.S., Neumann J., Jung A., Huels D., Olson M.F., Das S., Nibbs R.J., Sansom O.J. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J. Clin. Invest. 2012, 122:3127.
110. Browning J.L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. 2006, 5:564.
111. Zou W., Restifo N.P. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 2010, 10:248.
112. Gnerlich J.L., Mitchem J.B., Weir J.S., Sankpal N.V., Kashiwagi H., Belt B.A., Porembka M.R., Herndon J.M., Eberlein T.J., Goedegebuure P., Linehan D.C. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J. Immunol. 2010, 185:4063.
113. Takaku S., Terabe M., Ambrosino E., Peng J., Lonning S., McPherson J.M., Berzofsky J.A. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int. J. Cancer 2010, 126:1666.
114. Kesselring R., Thiel A., Pries R., Trenkle T., Wollenberg B. Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br. J. Cancer 2010, 103:1245.
115. Chung A.S., Wu X., Zhuang G., Ngu H., Kasman I., Zhang J., Vernes J.M., Jiang Z., Meng Y.G., Peale F.V., Ouyang W., Ferrara N. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 2013, 19:1114.
116. Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., Drake C., Pardoll D., Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009, 15:114.
117. Kirkwood J.M., Butterfield L.H., Tarhini A.A., Zarour H., Kalinski P., Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J. Clin. 2012, 62:309.
118. Lotze M.T., Chang A.E., Seipp C.A., Simpson C., Vetto J.T., Rosenberg S.A. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 1986, 256:3117.
119. Pizza G., Severini G., Menniti D., De V.C., Corrado F. Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int. J. Cancer 1984, 34:359.
120. Dillman R.O., Church C., Oldham R.K., West W.H., Schwartzberg L., Birch R. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993, 71:2358.
121. Rosenberg S.A., Lotze M.T., Yang J.C., Aebersold P.M., Linehan W.M., Seipp C.A., White D.E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 1989, 210:474.
122. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994, 271:907.
123. Mier J.W., Vachino G., van der Meer J.W., Numerof R.P., Adams S., Cannon J.G., Bernheim H.A., Atkins M.B., Parkinson D.R., Dinarello C.A. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J. Clin. Immunol. 1988, 8:426.
124. Zorn E., Nelson E.A., Mohseni M., Porcheray F., Kim H., Litsa D., Bellucci R., Raderschall E., Canning C., Soiffer R.J., Frank D.A., Ritz J. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006, 108:1571.
125. Zheng S.G., Wang J., Wang P., Gray J.D., Horwitz D.A. IL-2 is essential for TGF-beta to convert naive CD4+. J. Immunol. 2007, 178:2018.
126. Budagian V., Bulanova E., Paus R., Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 2006, 17:259.
127. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006, 6:595.
128. Steel J.C., Waldmann T.A., Morris J.C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 2012, 33:35.
129. Gill S., Berry S., Biagi J., Butts C., Buyse M., Chen E., Jonker D., Marginean C., Samson B., Stewart J., Thirlwell M., Wong R., Maroun J.A. Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Curr. Oncol. 2011, 18(Suppl. 2):S5-S10.
130. Fleming T.R., Rothmann M.D., Lu H.L. Issues in using progression-free survival when evaluating oncology products. J. Clin. Oncol. 2009, 27:2874.
131. Rosenberg S.A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233:1318.
132. Souza S.L., Montalli Da Assumpção L.V., Ward L.S. Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. Thyroid 2003, 13:491.
133. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., Panagiotou P., Polyzos A., Papadopoulos O., Stratigos A., Markopoulos C., Bafaloukos D., Pectasides D., Fountzilas G., Kirkwood J.M. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 2006, 354:709.
134. Krauze M.T., Tarhini A., Gogas H., Kirkwood J.M. Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin. Immunopathol. 2011, 33:385.
135. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol. Immunother. 2009, 58:823.
136. Nesslinger N.J., Sahota R.A., Stone B., Johnson K., Chima N., King C., Rasmussen D., Bishop D., Rennie P.S., Gleave M., Blood P., Pai H., Ludgate C., Nelson B.H. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin. Cancer Res. 2007, 13:1493.
137. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F.J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J.P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., Andre F., Delaloge S., Tursz T., Kroemer G., Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050.
138. Zitvogel L., Apetoh L., Ghiringhelli F., Andre F., Tesniere A., Kroemer G. The anticancer immune response: indispensable for therapeutic success?. J. Clin. Invest. 2008, 118:1991.
139. Ma Y., Kepp O., Ghiringhelli F., Apetoh L., Aymeric L., Locher C., Tesniere A., Martins I., Ly A., Haynes N.M., Smyth M.J., Kroemer G., Zitvogel L. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin. Immunol. 2010, 22:113.
140. Ascierto P.A., Capone M., Urba W.J., Bifulco C.B., Botti G., Lugli A., Marincola F.M., Ciliberto G., Galon J., Fox B.A. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J. Transl. Med. 2013, 11:54.
141. Galon J., Mlecnik B., Bindea G., Angell H.K., Berger A., Lagorce C., Lugli A., Zlobec I., Hartmann A., Bifulco C., Nagtegaal I.D., Palmqvist R., Masucci G.V., Botti G., Tatangelo F., Delrio P., Maio M., Laghi L., Grizzi F., Asslaber M., D'Arrigo C., Vidal-Vanaclocha F., Zavadova E., Chouchane L., Ohashi P.S., Hafezi-Bakhtiari S., Wouters B.G., Roehrl M., Nguyen L., Kawakami Y., Hazama S., Okuno K., Ogino S., Gibbs P., Waring P., Sato N., Torigoe T., Itoh K., Patel P.S., Shukla S.N., Wang Y., Kopetz S., Sinicrope F.A., Scripcariu V., Ascierto P.A., Marincola F.M., Fox B.A., Pages F. Towards the introduction of the Immunoscore in the classification of malignant tumors. J. Pathol. 2013, 232(2):199-209. 10.1002/path.4287.
142. Callahan M.K., Wolchok J.D. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J. Leukoc. Biol. 2013, 94:41.
143. Lee Y.K., Mukasa R., Hatton R.D., Weaver C.T. Developmental plasticity of Th17 and Treg cells. Curr. Opin. Immunol. 2009, 21:274.
144. Wilke C.M., Kryczek I., Wei S., Zhao E., Wu K., Wang G., Zou W. Th17 cells in cancer: help or hindrance?. Carcinogenesis 2011, 32:643.
145. Yang X.O., Nurieva R., Martinez G.J., Kang H.S., Chung Y., Pappu B.P., Shah B., Chang S.H., Schluns K.S., Watowich S.S., Feng X.H., Jetten A.M., Dong C. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008, 29:44.
146. Lexberg M.H., Taubner A., Forster A., Albrecht I., Richter A., Kamradt T., Radbruch A., Chang H.D. Th memory for interleukin-17 expression is stable in vivo. Eur. J. Immunol. 2008, 38:2654.
147. Zhang L., Feng D., Yu L.X., Tsung K., Norton J.A. Preexisting antitumor immunity augments the antitumor effects of chemotherapy. Cancer Immunol. Immunother. 2013, 62:1061.
148. Atkins M.B., Robertson M.J., Gordon M., Lotze M.T., DeCoste M., DuBois J.S., Ritz J., Sandler A.B., Edington H.D., Garzone P.D., Mier J.W., Canning C.M., Battiato L., Tahara H., Sherman M.L. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 1997, 3:409.
149. Osaki T., Peron J.M., Cai Q., Okamura H., Robbins P.D., Kurimoto M., Lotze M.T., Tahara H. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J. Immunol. 1998, 160:1742.
150. Okamura H., Tsutsi H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., Torigoe K., Okura T., Nukada Y., Hattori K. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995, 378:88.
151. Vidal-Vanaclocha F., Mendoza L., Telleria N., Salado C., Valcarcel M., Gallot N., Carrascal T., Egilegor E., Beaskoetxea J., Dinarello C.A. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev. 2006, 25:417.
152. Park S., Cheon S., Cho D. The dual effects of interleukin-18 in tumor progression. Cell. Mol. Immunol. 2007, 4:329.
153. Terme M., Ullrich E., Aymeric L., Meinhardt K., Desbois M., Delahaye N., Viaud S., Ryffel B., Yagita H., Kaplanski G., Prevost-Blondel A., Kato M., Schultze J.L., Tartour E., Kroemer G., Chaput N., Zitvogel L. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 2011, 71:5393.
154. Terme M., Ullrich E., Aymeric L., Meinhardt K., Coudert J.D., Desbois M., Ghiringhelli F., Viaud S., Ryffel B., Yagita H., Chen L., Mecheri S., Kaplanski G., Prevost-Blondel A., Kato M., Schultze J.L., Tartour E., Kroemer G., Degli-Esposti M., Chaput N., Zitvogel L. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res. 2012, 72:2757.
155. Moller B., Paulukat J., Nold M., Behrens M., Kukoc-Zivojnov N., Kaltwasser J.P., Pfeilschifter J., Muhl H. Interferon-gamma induces expression of interleukin-18 binding protein in fibroblast-like synoviocytes. Rheumatology (Oxford) 2003, 42:442.
156. Alagkiozidis I., Facciabene A., Tsiatas M., Carpenito C., Benencia F., Adams S., Jonak Z., June C.H., Powell D.J., Coukos G. Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J. Transl. Med. 2011, 9:77.
157. Simpkins F., Flores A.M., Chu C., Lucci J.A., Berek J.S., Coukos G., Bauman J.W., Murray S.C., Struemper H., Germaschewski F., Jonak Z., Gardner O.S., Toso J.F. A Phase I. Dose Escalation Trial to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) in Combination With Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer. 2012, 12A.D. p.abstr 5065.
158. Ni J., Miller M., Stojanovic A., Garbi N., Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J. Exp. Med. 2012, 209:2351.
159. Wong J.L., Berk E., Edwards R.P., Kalinski P. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res. 2013, 73:4653.
160. Robertson M.J., Kirkwood J.M., Logan T.F., Koch K.M., Kathman S., Kirby L.C., Bell W.N., Thurmond L.M., Weisenbach J., Dar M.M. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin. Cancer Res. 2008, 14:3462.
161. Son Y.I., Dallal R.M., Mailliard R.B., Egawa S., Jonak Z.L., Lotze M.T. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res. 2001, 61:884.
162. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6:506.
163. Scheel C., Eaton E.N., Li S.H., Chaffer C.L., Reinhardt F., Kah K.J., Bell G., Guo W., Rubin J., Richardson A.L., Weinberg R.A. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926.